Target |
Mechanism SLC6A2 modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date25 Mar 1994 |
Target |
Mechanism PSMA inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SSTR agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Dec 2015 |
Sponsor / Collaborator |
Start Date04 Jul 2013 |
Sponsor / Collaborator |
Start Date09 Apr 2013 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Yttrium 90-labelled edotreotide ( SSTR ) | malignant carcinoid tumor of digestive tract More | Discontinued |
[124I]mIBG | Neuroendocrine Tumors More | Discontinued |
BIO-130 | Cerebrovascular Disorders More | Discontinued |
Iobenguane I-131 ( NET ) | High Risk Neuroblastoma More | Discontinued |
Ioflubenzamide I-131 | Metastatic melanoma More | Discontinued |